Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paras H Shah

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
The Journal of Urology|June 2, 2018
The Association of Aspirin Use with Survival Following Radical CystectomyTimothy D Lyon, Igor Frank, Paras H Shah, et al.
Urologic Oncology|January 26, 2019
Comprehensive characterization of perioperative reoperation following radical cystectomyTimothy D Lyon, Stephen A Boorjian, Paras H Shah, et al.
The Prostate|August 1, 2020
Adding carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomesMohamed E Ahmed, Jack R Andrews, Jamal Alamiri, et al.
Urologic Oncology|November 18, 2025
Real-world outcomes of nadofaragene firadenovec for BCG-unresponsive non-muscle-invasive bladder cancer: A multicenter experienceJacob A Moyer, Lanyu Mi, Mimi V Nguyen, et al.
The Journal of Urology|May 1, 2018
Symptomatic Venous Thromboembolism is Associated with Inferior Survival among Patients Undergoing Nephrectomy with Inferior Vena Cava Tumor Thrombectomy for Renal Cell CarcinomaParas H Shah, R Houston Thompson, Stephen A Boorjian, et al.
The Journal of Urology|June 26, 2025
Use of Rectal Diazepam to Prevent Bladder Spasms and Leakage of Medication During Intravesical Administration of Nadofaragene Firadenovec for BCG-Unresponsive Non-Muscle-Invasive Bladder CancerJacob A Moyer, Adri M Durant, Mimi V Nguyen, et al.
Urologic Oncology|September 20, 2018
Risk prediction models for cancer-specific survival following cytoreductive nephrectomy in the contemporary eraTimothy D Lyon, Boris Gershman, Paras H Shah, et al.
Urologic Oncology|November 9, 2021
Collecting duct carcinoma: A single-institution retrospective studyZhuoer Xie, Siddhartha Yadav, Christine M Lohse, et al.
Urology|November 27, 2022
Perioperative and Oncologic Outcomes Associated with Simultaneous Radical Cystectomy and NephroureterectomyCameron J Britton, Harrison C Gottlich, Robert F Tarrell, et al.
World Journal of Urology|November 5, 2018
A risk-stratified approach to neoadjuvant chemotherapy in muscle-invasive bladder cancer: implications for patients classified with low-risk diseaseTimothy D Lyon, Igor Frank, Vidit Sharma, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
The Journal of Urology|June 2, 2018
The Association of Aspirin Use with Survival Following Radical CystectomyTimothy D Lyon, Igor Frank, Paras H Shah, et al.
Urologic Oncology|January 26, 2019
Comprehensive characterization of perioperative reoperation following radical cystectomyTimothy D Lyon, Stephen A Boorjian, Paras H Shah, et al.
The Prostate|August 1, 2020
Adding carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomesMohamed E Ahmed, Jack R Andrews, Jamal Alamiri, et al.
Urologic Oncology|November 18, 2025
Real-world outcomes of nadofaragene firadenovec for BCG-unresponsive non-muscle-invasive bladder cancer: A multicenter experienceJacob A Moyer, Lanyu Mi, Mimi V Nguyen, et al.
The Journal of Urology|May 1, 2018
Symptomatic Venous Thromboembolism is Associated with Inferior Survival among Patients Undergoing Nephrectomy with Inferior Vena Cava Tumor Thrombectomy for Renal Cell CarcinomaParas H Shah, R Houston Thompson, Stephen A Boorjian, et al.
The Journal of Urology|June 26, 2025
Use of Rectal Diazepam to Prevent Bladder Spasms and Leakage of Medication During Intravesical Administration of Nadofaragene Firadenovec for BCG-Unresponsive Non-Muscle-Invasive Bladder CancerJacob A Moyer, Adri M Durant, Mimi V Nguyen, et al.
Urologic Oncology|September 20, 2018
Risk prediction models for cancer-specific survival following cytoreductive nephrectomy in the contemporary eraTimothy D Lyon, Boris Gershman, Paras H Shah, et al.
Urologic Oncology|November 9, 2021
Collecting duct carcinoma: A single-institution retrospective studyZhuoer Xie, Siddhartha Yadav, Christine M Lohse, et al.
Urology|November 27, 2022
Perioperative and Oncologic Outcomes Associated with Simultaneous Radical Cystectomy and NephroureterectomyCameron J Britton, Harrison C Gottlich, Robert F Tarrell, et al.
World Journal of Urology|November 5, 2018
A risk-stratified approach to neoadjuvant chemotherapy in muscle-invasive bladder cancer: implications for patients classified with low-risk diseaseTimothy D Lyon, Igor Frank, Vidit Sharma, et al.
Pageof 5